[go: up one dir, main page]

DE60336934D1 - Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten - Google Patents

Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten

Info

Publication number
DE60336934D1
DE60336934D1 DE60336934T DE60336934T DE60336934D1 DE 60336934 D1 DE60336934 D1 DE 60336934D1 DE 60336934 T DE60336934 T DE 60336934T DE 60336934 T DE60336934 T DE 60336934T DE 60336934 D1 DE60336934 D1 DE 60336934D1
Authority
DE
Germany
Prior art keywords
increasing
igf
preparation
treatment
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336934T
Other languages
English (en)
Inventor
Hubert Jean-Marie Francois Gillessen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veijlen N V
Original Assignee
Veijlen N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veijlen N V filed Critical Veijlen N V
Application granted granted Critical
Publication of DE60336934D1 publication Critical patent/DE60336934D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
DE60336934T 2003-10-03 2003-10-03 Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten Expired - Lifetime DE60336934D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/011171 WO2005039546A2 (en) 2003-10-03 2003-10-03 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases

Publications (1)

Publication Number Publication Date
DE60336934D1 true DE60336934D1 (de) 2011-06-09

Family

ID=34429223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336934T Expired - Lifetime DE60336934D1 (de) 2003-10-03 2003-10-03 Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten

Country Status (15)

Country Link
US (2) US9408405B2 (de)
EP (1) EP1670444B1 (de)
JP (1) JP4641942B2 (de)
CN (1) CN1938018B (de)
AT (1) ATE506948T1 (de)
AU (1) AU2003273967A1 (de)
CA (1) CA2541090C (de)
CY (1) CY1116665T1 (de)
DE (1) DE60336934D1 (de)
DK (1) DK1670444T3 (de)
ES (2) ES2365847T3 (de)
PT (2) PT1670444E (de)
RU (1) RU2345552C2 (de)
SI (1) SI1670444T1 (de)
WO (1) WO2005039546A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034942A1 (en) 2003-10-03 2005-04-21 Veijlen N.V. Animal feed composition
SI1670444T1 (sl) 2003-10-03 2011-09-30 Veijlen N V Uporaba derivatov indolocetne kisline, ki zvišajo serumsko raven IGF-1,za pripravo terapevtskega sestavka za zdravljenje različnih bolezni
JPWO2005049006A1 (ja) * 2003-11-21 2007-11-29 味の素株式会社 糖尿病治療剤
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
RU2339378C1 (ru) * 2007-02-16 2008-11-27 Российская военно-медицинская академия им. С.М. Кирова ПРИМЕНЕНИЕ ГИДРОБРОМИДА 2-АМИНО-7-БРОМ-4-АЦЕТИЛТИАЗОЛО[5,4-b]ИНДОЛА ДЛЯ ПОВЫШЕНИЯ РАБОТОСПОСОБНОСТИ
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US9063122B2 (en) * 2008-10-17 2015-06-23 Alfredo Gallegos Biomodulators for treatment or prevention of disease
BRPI1011245B1 (pt) 2009-06-11 2020-03-24 Dsm Ip Assets B.V. Uso de trigonelina como um estimulante muscular.
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
HK1215179A1 (zh) 2012-11-26 2016-08-19 国立大学法人东北大学 促红细胞生成素表达增强剂
RU2524634C1 (ru) * 2013-06-25 2014-07-27 Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук Способ стимуляции роста птицы
KR102313381B1 (ko) * 2013-12-19 2021-10-14 퓨어테인 바이오사이언스, 엘엘씨. 동물을 치료하기 위한 방법
KR102265412B1 (ko) * 2014-08-13 2021-06-14 주식회사 엘지생활건강 그라민 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
KR20170094238A (ko) * 2014-12-16 2017-08-17 퓨어테인 바이오사이언스, 엘엘씨. 동물에서 혈청 igf-1을 증가시키는 방법
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US11730795B2 (en) * 2017-08-09 2023-08-22 Intervene Immune Inc. Pharmaceuticals and dosing means for human aging reversal
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3893893A1 (de) * 2018-12-13 2021-10-20 Aim Immunotech Inc. Verfahren zur verbesserung der trainingstoleranz bei patienten mit encephalomyelitis
CN114040767A (zh) * 2019-01-30 2022-02-11 钻石治疗公司 用于治疗心理、认知、行为和/或情绪障碍的包含5ht受体激动剂的方法和组合物
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
CN111407884B (zh) * 2019-06-24 2021-12-07 浙江大学 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途
JP2022547948A (ja) * 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
KR20220092509A (ko) 2019-10-01 2022-07-01 엠피리언 뉴로사이언스, 인크. 트립타민 발현을 조절하는 균류의 유전자 공학
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
US20220132902A1 (en) * 2020-08-12 2022-05-05 Pharmavite, Llc Prebiotic composition of pectin, beta-glucan, xylooligosaccharide and/or ashwagandha and a method of improving mood
WO2022047580A1 (en) 2020-09-01 2022-03-10 Magicmed Industries Inc. Hydroxylated psilocybin derivatives and methods of using
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
WO2023130076A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Targets and pathways for the production of alkaloidal compounds
EP4486448A1 (de) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-kristalle oder salze mit psilocin
CN114870018A (zh) * 2022-05-12 2022-08-09 江南大学 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用
CN115813918B (zh) * 2022-09-30 2024-04-02 中国药科大学 吲哚乙酸在制备抑郁症治疗药物中的应用
CN117159528A (zh) * 2023-01-13 2023-12-05 再造再生健康科技(杭州)有限公司 用于促进提高内源类胰岛素样生长因子1分泌的组合物
CN116124950B (zh) * 2023-02-22 2025-02-21 复旦大学 用于生长激素注射筛查或检测的血清生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA957281A (en) * 1970-02-03 1974-11-05 Nathan N. Share Pharmaceutical compositions containing indole-3-acetic acid derivatives as a skeletal muscle stimulant
US4025650A (en) 1975-11-24 1977-05-24 Control Drug, Inc. Method and composition for preventing nutritional deficiency
GB1475861A (en) * 1976-03-19 1977-06-10 Warner Lambert Co Pharmaceutical composition
GB1535778A (en) * 1976-12-06 1978-12-13 Mac Sweeney D Compounds useful in treatment of unipolar depression
JPS60199801A (ja) 1984-03-24 1985-10-09 Masaki Kamata 動物に対する植物成長ホルモンの投与方法
US4687763A (en) * 1985-02-25 1987-08-18 Massachusetts Institute Of Technology Composition and method for increasing levels or release of brain serotonin
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
BE1000990A3 (nl) 1987-10-09 1989-05-30 Picanol Nv Inrichting voor het op elkaar aansluiten van onderling verplaatsbare elementen, en transportinrichting die eerstgenoemde inrichting toepast.
GB8727099D0 (en) * 1987-11-19 1987-12-23 Cellena Cell Eng A G Compositions containing melantonin/homologues
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
IT1237472B (it) * 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
US5132113A (en) 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
EP0608362A1 (de) * 1991-10-18 1994-08-03 Alza Corporation Vorrichtung zur transdermalen verabreichung von melatomin
GB9214419D0 (en) 1992-07-07 1992-08-19 Concannon Peter Biocidal agents
JPH0725838A (ja) * 1993-05-13 1995-01-27 Yotsuba Yuka Kk 疲労の予防または回復のための経口投与剤
JP3541969B2 (ja) 1994-09-29 2004-07-14 東洋紡績株式会社 ベットマット
JP3617102B2 (ja) * 1995-01-27 2005-02-02 味の素株式会社 ヒト筋肉疲労の早期回復効果を有するアミノ酸栄養組成物
JPH08308580A (ja) * 1995-05-17 1996-11-26 Takeda Chem Ind Ltd 組換え型ヒトｇｈｒｈレセプター蛋白質、その製造法および用途
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
FR2741799B1 (fr) * 1995-12-04 1998-01-02 Oreal Utilisation de melatonine dans une composition pour traiter les signes cutanes des etats de fatigue
ATE245999T1 (de) * 1996-01-09 2003-08-15 Riken Aminosäurezusammensetzungen
FR2746313B1 (fr) * 1996-03-22 1998-04-17 Adir Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques
US5958964A (en) 1997-02-18 1999-09-28 South Alabama Medical Science Foundation Use of melatonin to prevent cytotoxic effects of amyloid beta protein
DE19739763A1 (de) * 1997-09-10 1999-09-23 Franz Uhl Vitamin B3/Niacin zur Behandlung von Krankheiten
US6017946A (en) * 1997-10-08 2000-01-25 Posner; Robert Serotonin containing formulation for oral administration and method of use
EP1159292A2 (de) 1998-08-14 2001-12-05 Administrators of The Tulane Educational Fund Verbindungen mit wachstumshormonsbefreiender wirkung
JP2002524402A (ja) * 1998-09-03 2002-08-06 ニューロンズ・リミテッド 神経保護
IL132366A0 (en) 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
CN1069050C (zh) * 1998-12-01 2001-08-01 周旭生 一种治疗糖尿病的中药复方制剂
EP1135123B1 (de) 1998-12-04 2004-12-29 Neurosearch A/S Verwendung von isatinderivaten als ionenkanalaktivierende mittel
FR2795323B1 (fr) * 1999-06-23 2001-11-16 Adir Utilisation de ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention ou au traitement des pathologies du systeme gastrointestinal
JP2001026579A (ja) * 1999-07-13 2001-01-30 Kobe Tennenbutsu Kagaku Kk インドール酢酸類の製造方法
CN1088597C (zh) * 1999-10-26 2002-08-07 合肥永生制药有限公司 尿多酸肽组合物及其用途
US20020155163A1 (en) * 1999-12-27 2002-10-24 Samuel D. Benjamin Integrated multi-vitamin and mineral combination
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
DE10037773C1 (de) * 2000-08-03 2002-08-22 Hennecke Gmbh Verfahren und Vorrichtung zum Herstellen von mit Langfasern verstärkten Kunststoff-Formteilen
DE10109798A1 (de) 2001-03-01 2002-09-12 Aventis Pharma Gmbh Gesundheitsfördernde Zusammensetzung von Verbindungen
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
JP2002281914A (ja) * 2001-03-27 2002-10-02 Nishi Nippon Green Kk 魚類、家畜類の栄養活力促進剤の製造方法
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
CN1408397A (zh) * 2001-09-26 2003-04-09 北京本元青阳生物科技发展有限公司 含褪黑素和益智中药的组合物
JP2003137808A (ja) * 2001-10-26 2003-05-14 Kakunai Juyotai Kenkyusho:Kk 新規経腸栄養剤の製造法
JP2005522466A (ja) * 2002-03-18 2005-07-28 ファルマシア・コーポレーション アルドステロン受容体アンタゴニスト、およびニコチン酸またはニコチン酸誘導体の組合わせ
CN1440744A (zh) * 2003-02-15 2003-09-10 高景曦 纳米包覆退黑激素复合保健品
JP4828414B2 (ja) 2003-04-28 2011-11-30 ニツポネツクス・インコーポレーテツド インドール酢酸誘導体および薬剤としてのそれらの使用
SI1670444T1 (sl) 2003-10-03 2011-09-30 Veijlen N V Uporaba derivatov indolocetne kisline, ki zvišajo serumsko raven IGF-1,za pripravo terapevtskega sestavka za zdravljenje različnih bolezni
WO2005034942A1 (en) 2003-10-03 2005-04-21 Veijlen N.V. Animal feed composition

Also Published As

Publication number Publication date
WO2005039546A3 (en) 2007-10-04
RU2006114743A (ru) 2007-11-10
US10716778B2 (en) 2020-07-21
AU2003273967A8 (en) 2005-05-11
ATE506948T1 (de) 2011-05-15
CY1116665T1 (el) 2017-03-15
HK1103963A1 (zh) 2008-01-04
AU2003273967A1 (en) 2005-05-11
JP4641942B2 (ja) 2011-03-02
ES2365847T3 (es) 2011-10-11
US20160331725A1 (en) 2016-11-17
ES2326595T3 (es) 2009-10-15
RU2345552C2 (ru) 2009-02-10
SI1670444T1 (sl) 2011-09-30
CA2541090C (en) 2013-04-16
PT1667678E (pt) 2009-08-05
CA2541090A1 (en) 2005-05-06
EP1670444A2 (de) 2006-06-21
CN1938018A (zh) 2007-03-28
US9408405B2 (en) 2016-08-09
EP1670444B1 (de) 2011-04-27
US20080194553A1 (en) 2008-08-14
JP2007525405A (ja) 2007-09-06
DK1670444T3 (da) 2011-08-22
PT1670444E (pt) 2011-07-29
CN1938018B (zh) 2010-09-01
WO2005039546A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
DE60336934D1 (de) Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
Sears Chelation: harnessing and enhancing heavy metal detoxification—a review
Saini Coenzyme Q10: The essential nutrient
NO20063328L (no) Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
EA200501710A1 (ru) Замещённые карбоновые кислоты
HU228847B1 (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
EA200400881A1 (ru) Азаарилпиперазины
JP2008179620A (ja) 筋萎縮抑制剤
JP4366527B2 (ja) 特に眼科分野における適用のための外傷および損傷の治癒および／または修復のための治療に適したアミノ酸組成物
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
CN105381039A (zh) 一种治疗原发性骨质疏松症的中药组合物及其制备方法
JP2003212765A (ja) 水虫の活動を停止させる溶液
US11414663B2 (en) Micro-RNA profiling, compositions, and methods of treating diseases
CN103110609A (zh) 一种治疗口腔溃疡的涂膜剂及其制备方法
WO2019026930A1 (ja) 筋量増加用食品組成物、筋量増加剤、ロコモティブシンドローム治療剤、サルコペニア治療剤、運動機能維持剤、筋萎縮関連遺伝子発現抑制剤、筋タンパク質分解抑制剤、筋萎縮予防剤、筋合成関連遺伝子発現促進剤及び筋合成促進剤
US10744151B1 (en) Micro-RNA profiling, compositions, and methods of treating diseases
Chauveau et al. Common therapeutic approaches of sarcopenia in the elderly and uremic myopathy
CN1201769C (zh) 治疗糖尿病、肾病的药物
US20230040823A1 (en) Micro-rna profiling, compositions, and methods of treating diseases
CN1299707C (zh) 一种银黄口服液及其生产工艺
JP2007031302A (ja) アディポネクチン産生促進剤、及び代謝異常症候群予防剤
CN1255115C (zh) 含铈治疗痤疮的药剂及其制法
CN101143203A (zh) 一种具有护肝养胃功能的复方口服液
Ibrahim The Impact of Concomitant administration of Antiarrhythmic agent (Amiodarone) with Mustard oil on thyroid gland in Experimental Animals